Cargando…
Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?
Individualising biologic disease-modifying anti-rheumatic drugs (bDMARDs) to maximise outcomes and deliver safe and cost-effective care is a key goal in the management of rheumatoid arthritis (RA). Investigation to identify predictive tools of bDMARD response is a highly active and prolific area of...
Autores principales: | Romão, Vasco C., Vital, Edward M., Fonseca, João Eurico, Buch, Maya H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655983/ https://www.ncbi.nlm.nih.gov/pubmed/29065909 http://dx.doi.org/10.1186/s13075-017-1445-3 |
Ejemplares similares
-
Response measures influence comparative effectiveness of biological drugs in rheumatoid arthritis
por: Canhao, Helena, et al.
Publicado: (2012) -
Disease mechanisms in preclinical rheumatoid arthritis: A narrative review
por: Romão, Vasco C., et al.
Publicado: (2022) -
Etiology and Risk Factors for Rheumatoid Arthritis: A State-of-the-Art Review
por: Romão, Vasco C., et al.
Publicado: (2021) -
Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?
por: Romão, Vasco Crispim, et al.
Publicado: (2013) -
Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient—Companion Diagnostics
por: Meehan, Richard Thomas, et al.
Publicado: (2021)